Why the study?
Cutaneous angiosarcoma typically portends a poor prognosis at diagnosis, and adjunctive oral propranolol may offer benefit similar to its efficacy in infantile hemangiomas.
Does adjunctive oral propranolol improve outcomes in patients with cutaneous angiosarcoma?
Does adjunctive oral propranolol improve outcomes in patients with cutaneous angiosarcoma?
Oral propranolol may be a promising adjunctive therapy for cutaneous angiosarcoma.
Should not change practice for cutaneous angiosarcoma; hypothesis-generating and requires prospective validation.
Although cutaneous angiosarcoma typically portends a poor prognosis at the time of diagnosis, adjunctive oral propranolol may be a promising and relatively benign therapy, posited to afford benefit in a manner similar to its efficacy in the treatment of infantile hemangiomas.
No takes yet. Share an insight, caveat, or question.
Nyers (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: